XYZAL ALLERGY 24HR Drug Patent Profile
✉ Email this page to a colleague
When do Xyzal Allergy 24hr patents expire, and what generic alternatives are available?
Xyzal Allergy 24hr is a drug marketed by Chattem Sanofi and is included in two NDAs. There is one patent protecting this drug.
The generic ingredient in XYZAL ALLERGY 24HR is levocetirizine dihydrochloride. There is one drug master file entry for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xyzal Allergy 24hr
A generic version of XYZAL ALLERGY 24HR was approved as levocetirizine dihydrochloride by SYNTHON BV on November 26th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for XYZAL ALLERGY 24HR?
- What are the global sales for XYZAL ALLERGY 24HR?
- What is Average Wholesale Price for XYZAL ALLERGY 24HR?
Summary for XYZAL ALLERGY 24HR
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Patent Applications: | 331 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XYZAL ALLERGY 24HR |
| What excipients (inactive ingredients) are in XYZAL ALLERGY 24HR? | XYZAL ALLERGY 24HR excipients list |
| DailyMed Link: | XYZAL ALLERGY 24HR at DailyMed |
Pharmacology for XYZAL ALLERGY 24HR
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for XYZAL ALLERGY 24HR
XYZAL ALLERGY 24HR is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi | XYZAL ALLERGY 24HR | levocetirizine dihydrochloride | SOLUTION;ORAL | 209090-001 | Jan 31, 2017 | OTC | Yes | Yes | 8,633,194 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Chattem Sanofi | XYZAL ALLERGY 24HR | levocetirizine dihydrochloride | TABLET;ORAL | 209089-001 | Jan 31, 2017 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XYZAL ALLERGY 24HR
See the table below for patents covering XYZAL ALLERGY 24HR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 049846 | PREPARACIONES FARMACEUTICAS DE DERIVADOS DE LA PIPERAZINA | ⤷ Start Trial |
| Austria | E443512 | ⤷ Start Trial | |
| Australia | 2005261953 | Pharmaceutical composition of piperazine derivatives | ⤷ Start Trial |
| Brazil | PI0513257 | composição farmacêutica lìquida | ⤷ Start Trial |
| Canada | 2573662 | COMPOSITION PHARMACEUTIQUE A BASE DE DERIVES DE PIPERAZINE (PHARMACEUTICAL COMPOSITION OF PIPERAZINE DERIVATIVES) | ⤷ Start Trial |
| China | 100508981 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XYZAL ALLERGY 24HR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0058146 | 2001C/045 | Belgium | ⤷ Start Trial | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| 0663828 | C300085 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch